ReproductiveFDA Approved

Goserelin (Zoladex)

Subcutaneous implant

Overview

A synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug release over 1 or 3 months. Like other GnRH agonists, goserelin initially stimulates and then suppresses the HPG axis, reducing sex hormone production to castrate or postmenopausal levels.

Mechanism of Action

The implant formulation eliminates the need for repeated injections and ensures compliance..

Research Summary & Key Findings

FDA-approved for prostate cancer, breast cancer, endometriosis, and endometrial thinning. The 10.8 mg depot provides 3 months of sustained hormone suppression. Equivalent efficacy to surgical castration in prostate cancer with the advantage of reversibility. Used as adjuvant therapy with radiation in locally advanced prostate cancer based on landmark trials (Bolla et al., NEJM, 1997).

Clinical Status

FDA Approved

Goserelin (Zoladex) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous implant

Related Peptides in Reproductive

Find a Provider

Find a verified provider who offers Goserelin (Zoladex) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Goserelin (Zoladex).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.